Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

2.0K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.0K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

2.5K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.5K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

2.2K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.2K
Drug Therapy01:28

Drug Therapy

440
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
440
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

693
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
693

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Birds may represent a useful animal model for studying human mental disorders.

Acta neuropsychiatrica·2025
Same author

Major Limitations of Randomized Controlled Trials Assessing Antidepressant Efficacy.

Journal of clinical psychopharmacology·2025
Same author

Comment on Martino et al. "Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations".

Movement disorders : official journal of the Movement Disorder Society·2023
Same author

Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia.

Diagnostics (Basel, Switzerland)·2022
Same author

The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia.

Genes·2022
Same author

Cytokine level in patients with mood disorder, alcohol use disorder and their comorbidity.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry·2022

Related Experiment Video

Updated: Apr 23, 2026

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

1.0K

Utility of Antidepressant Randomized Controlled Trials for Regular Treatment.

Anton J M Loonen1

  • 1Pharmacotherapy, -Epidemiology & -Economics, University of Groningen, Groningen, Netherlands.

Pharmacopsychiatry
|April 21, 2026
PubMed
Summary

Randomised clinical trials (RCTs) used for drug approval have limitations in depression research. Pragmatic trials in drug treatment-naive patients are preferred for developing better antidepressant treatment guidelines.

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

31.8K

Related Experiment Videos

Last Updated: Apr 23, 2026

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

1.0K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

31.8K

Area of Science:

  • Clinical Psychology
  • Psychopharmacology
  • Evidence-Based Medicine

Background:

  • Current depression guidelines rely on randomized clinical trials (RCTs) for marketing authorization.
  • These RCTs possess limitations, including participant heterogeneity and inadequate control of natural resilience mechanisms.
  • This impacts the generalizability and applicability of existing depression treatment recommendations.

Purpose of the Study:

  • To advocate for a shift in the evidence base for antidepressant treatment guidelines.
  • To highlight the limitations of current randomized clinical trials in depression research.
  • To propose pragmatic trials as a superior alternative for guideline development.

Main Methods:

  • Critically evaluate the methodologies and limitations of standard randomized clinical trials in depression.
  • Identify the shortcomings in controlling for participant heterogeneity and natural resilience in existing trial designs.
  • Propose the utilization of pragmatic trials involving a consistent cohort of primary and secondary care reporters.

Main Results:

  • Randomized clinical trials exhibit significant heterogeneity among participants with depression.
  • Natural resilience mechanisms are not sufficiently controlled in standard RCTs.
  • These factors compromise the reliability of RCTs for informing clinical practice.

Conclusions:

  • Antidepressant treatment guidelines should be based on pragmatic trials, not solely on marketing authorization RCTs.
  • Pragmatic trials offer a more realistic and controlled approach by focusing on drug treatment-naive patients.
  • This approach enhances the clinical relevance and effectiveness of depression management strategies.